Bull Market Won't B...
Health Care: Drugs
Sarepta Therapeutics Inc (SRPT: NASDAQ)
$35.78 -1.35 | -3.64%
05/21/13 - 10:31 AM ET
Company Cash Flow
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Cash Flow From Operating Activities | ||||
|---|---|---|---|---|
| Net Income (Loss) | -121.29M | -2.32M | -32.18M | -25.16M |
| Operating Gains/Losses | 357.00K | 190.00K | 776.00K | 347.00K |
| Extraordinary Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Receivables | -3.59M | -1.06M | -1.21M | 2.62M |
| (Increase) Decrease in Inventories | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Other Current Assets | 0.00 | 0.00 | 0.00 | 0.00 |
| (Decrease) Increase In Payables | -1.72M | 8.00M | 861.00K | 312.00K |
| (Decrease) Increase In Other Current Liabilities | 91.94M | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Other Working Capital | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Non-Cash Items | 3.08M | -29.78M | 15.08M | 11.70M |
| Net Cash From Continuing Operations | -29.69M | -23.68M | -15.21M | -8.80M |
| Net Cash From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Provided By Investing Activities | ||||
| Net Cash From Total Operating Activities | -29.69M | -23.68M | -15.21M | -8.80M |
| Sale of Property, Plant & Equipment | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Used for Investing Activities | ||||
| Sale of Short-Term Investments | 0.00 | 0.00 | 0.00 | 111.00K |
| Purchases of Property, Plant & Equipment | -1.14M | -2.30M | -1.95M | -1.99M |
| Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchases of Short-Term Investments | 0.00 | 0.00 | -7.00K | 0.00 |
| Other Cash from Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Provided by Financing Activities | ||||
| Net Cash From Investing Activities | -1.14M | -2.30M | -1.96M | -1.88M |
| Issuance of Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Used for Financing Activities | ||||
| Issuance of Capital Stock | 178.68M | 32.38M | 2.56M | 47.84M |
| Repayment of Long-Term Debt | -85.00K | -81.00K | -77.00K | -74.00K |
| Repurchase of Capital Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Payment of Cash Dividends | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Charges, Net | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Cash From Financing Activities | 178.60M | 32.30M | 2.48M | 47.77M |
| Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Change in Cash & Cash Equivalents | 147.76M | 6.32M | -14.69M | 37.08M |
Portfolios with SRPT
- Portfolio NameUser Type
- ContributorStocks Rising On Unusual Vo...
- ContributorEarnings Short Squeeze Play...
- UserWatch
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks Rising On Unusual Vo...
- User2012 picks 10/28/20121
- UserKJP Save Stockpickr Fund
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks With Big Insider Buy...
Latest SRPT Headlines from TheStreet
- 2013 FDA Drug Approval Calendar 05.21.13 | 07:05 am
- Sarepta Therapeutics Inc (SRPT): Today's Featured Drugs Winner 05.16.13 | 05:05 pm
- Biotech Stock Mailbag: Synta, Zogenix, Sarepta, Amarin 05.10.13 | 07:05 am
- Leaders of TheStreet's Drug Approval Contest 05.06.13 | 09:05 am
- Sarepta Therapeutics Inc (SRPT): Today's Featured Drugs Winner 05.01.13 | 05:05 pm
- A DMD Expert and Mother Calls For Eteplirsen's Rapid Approval 04.26.13 | 09:04 am
- Biotech Stock Mailbag: ASCO, Sarepta, Cel-Sci and Hate Mail! 04.26.13 | 08:04 am
- Sarepta Therapeutics Inc (SRPT): Today's Featured Drugs Laggard 04.19.13 | 05:04 pm
- Stocks Rebound Mirrors Markets After Madrid, London Bombings 04.16.13 | 04:04 pm
- Sarepta Stock Gaps Down On Today's Open (SRPT) 04.16.13 | 09:04 am
Press Releases for SRPT
- Over $400 Million Raised By U.S. Life Sciences Companies Through At-the-Market (ATM) Offerings In 2012, Reports Brinson Patrick - PR Newswire 04.08.13 | 08:04 am
- Over 25 Companies To Present At Emerald Groundhog Day Investment Forum - Business Wire 02.05.13 | 10:02 am
Partner Headlines for SRPT
- Thursday's BioPharma Trade Movers - Seeking Alpha 04.18.13 | 09:04 am
- Muscular Dystrophy Drug Succeeds, Sarepta Buyers Flood In - Seeking Alpha 04.11.13 | 09:04 am
- Barron's Recap (3/23/13): World's Best CEOs - Benzinga 03.24.13 | 01:03 pm
- Sarepta Therapeutics Setting Up For Another Move Upward - Seeking Alpha 01.31.13 | 09:01 am
- Raptor To Rise On Proven Strategy & Upcoming FDA Decision - Seeking Alpha 12.28.12 | 09:12 am
- UPDATE: Burril Initiates Sarepta Therapeutics at Market Outperform on Eteplirsen Potential - Benzinga 11.26.12 | 09:11 am
- Sarepta Therapeutics to Present Additional 48-Week Data From the Phase IIb Study of Eteplirsen for Treatment of Duchenne Muscular Dystrophy - Benzinga 10.12.12 | 04:10 pm
- 5 Bio-Pharmas On The Rise With Potential Groundbreaking And Lifesaving Treatments - Seeking Alpha 10.09.12 | 09:10 am
- Benzinga Mid-Morning Market Update - Benzinga 10.05.12 | 01:10 pm
- 3 Interesting Moves In Biotech Stocks From Wednesday - Seeking Alpha 10.04.12 | 09:10 am
